Drug Target Discovery Technology | Protein Interference

SCIENTIFIC ANIMATION | Scientific storytelling & Product education

Phoremost’s technology aims to discover drug targets that remain intractable or undetected using conventional technologies, facilitating drug development for diseases such as cancer. Their novel SITESEEKER platform uses PROTEINi (or protein interference) – a new phenotypic screening method that identifies unexpected druggable sites that aren’t apparent with other technologies.

PROTEINi libraries encode millions of different proteins allowing identification of target-interaction sites throughout the whole proteome. This mechanism of action (MoA) animation shows how PROTEINi uses phenotypic screening to rapidly identify the key target-interaction sites involved in the disease being studied. This allows the discovery of novel drug targets including targets that were previously deemed ‘undruggable’.

This animation appears on the Phoremost technology page to showcase the potential of PROTEINi technology for drug discovery programs.

Are you interested in seeing how our award-winning medical animation can help you?

Random42 constantly strives to innovate in the medical animation space. Get in touch for a consultation on your next project.


cellectar logo

‘‘Extremely happy, everybody was great on the team. They answered all our questions and made it look easy. The end result is perfect.

Executive Coordinator, Cellectar Biosciences


‘‘The presentation was dramatically enhanced by the video, which looked fantastic on the big screen. Thank you and the entire Random42 team for your excellent work and for getting the final edition to me in time for the conference. All very much appreciated!

President and CEO, Vallum Corporation


‘‘The quality of the work produced by Random42 sets them apart and helps us quickly tell our scientific story more clearly. The high-quality production value is bolstered by their depth of knowledge. Together, that helps us tell the story of a complex disease and cell-based treatment and make it understandable to professionals and laypeople alike.’’

CEO, Brainstorm Cell Therapeutics

Phathom logo

‘‘Working with the Random42 team was a seamless collaboration, where they exhibited great project management skills, clear & thoughtful communication, and delivered high-quality work that was visually appealing. Our team was impressed with the final products!’’

Medical Affairs, Phathom Pharmaceuticals